t
| Date | 26 Sept 2022 |
| Time | 08:00:04 |
| Category | Capital structure |
| ID | 5362A |
26 September 2022
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology", or the "Company")
Admission and Total Voting Rights
Cizzle Biotechnology, the UK-based diagnostics developer, announces that further to the Company's announcement on 21 September 2022 the Subscription Shares, the Commission Shares and the Facility Shares, being a total of 35,666,665 new Ordinary Shares (together the "New Ordinary Shares") have today been admitted to the Official List of the FCA by means of a standard listing under Chapter 14 of the Listing Rules and to trading on the Main Market of the London Stock Exchange ("Admission").
Total Voting Rights
Following Admission of the New Ordinary Shares the total number of the Company's ordinary shares in issue is 314,114,453, each with equal voting rights. The Company does not hold any voting rights in treasury. The total voting rights figure can be used by Shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change of their interest in, the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.
Capitalised terms not otherwise defined in this announcement have the same meaning ascribed to them in the Company's announcement made on 21 September 2022.
Enquiries:
|
Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
|
Allan Syms (Executive Chairman) |
|
|
Allenby Capital Limited |
+44(0) 20 33285656 |
|
John Depasquale |
|
|
Alex Brearley |
|
|
Novum Securities Limited |
+44(0) 20 7399 9400 |
|
Colin Rowbury Jon Bellis |
|
|
IFC Advisory Limited |
+44(0) 20 3934 6630 |
|
Tim Metcalfe |
|
|
Florence Chandler |
|
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is also developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.